KODIAK SCIENCES INC. Debt Securities, Available-for-sale, Unrealized Loss
KODIAK SCIENCES INC. (KOD) reported Debt Securities, Available-for-sale, Unrealized Loss of $96.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2024-03-28
- KODIAK SCIENCES INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $96.00K.
- KODIAK SCIENCES INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was -$1.20M.
- KODIAK SCIENCES INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-09-30 was $636.00K.
- KODIAK SCIENCES INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $1.31M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2023-03-31 | $96.00K 10-Q · filed 2023-05-15 | -$1.10M derived: sum of 2 quarters · filed 2024-03-28 | -$466.00K derived: sum of 3 quarters · filed 2024-03-28 | |
| 2022-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$562.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.31M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.50M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $1.87M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |